Skip to main content
AAN.com
Articles
February 25, 2003

Major malformations in offspring of women with epilepsy

February 25, 2003 issue
60 (4) 575-579

Abstract

Background: The offspring of women with epilepsy are at an increased risk of major congenital malformations, but the impact of the various contributing factors remains unresolved.
Method: In 1980 through 1998, the authors prospectively followed up 970 pregnancies in women with epilepsy at a single maternity clinic. Of their 979 offspring, 740 were exposed to maternal antiepileptic drugs (AED) during the first trimester of pregnancy and 239 were not exposed. Maternal AED levels and serum folate concentrations were measured at the end of the first trimester. Logistic regression analysis was applied to identify factors associated with the occurrence of major malformations in the fetuses and newborns.
Results: Major malformations were detected in 28 fetuses (3.8%) exposed to maternal AED and in 2 (0.8%) not exposed (p = 0.02). After logistic regression analysis, the occurrence of major malformations was independently associated with use of carbamazepine (adjusted OR 2.5; 95% CI 1.0 to 6.0), use of valproate (4.1; 1.6 to 11), use of oxcarbazepine (10.8; 1.1 to 106), low serum folate concentration (5.8; 1.3 to 27), and low maternal level of education (3.0; 1.3 to 6.8). Major malformations were not associated with seizures during the first trimester (0.6; 0.1 to 2.9).
Conclusions: Major malformations in the offspring of mothers with epilepsy are associated with use of AED during early pregnancy, and also with low serum folate concentrations and a low level of education.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (et1.doc)
File (et2.doc)

References

1.
Russell AJC, Macpherson H, Cairnie V, Brodie MJ. The care of pregnant women with epilepsy—a survey of obstetricians in Scotland. Seizure . 1996; 5: 271–277.
2.
Zahn CA, Morrell MJ, Collins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy: a review of the literature. Neurology . 1998; 51: 949–956.
3.
Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res . 1999; 33: 145–158.
4.
Locksmith GJ, Duff P. Preventing neural tube defects: the importance of periconceptional folic acid supplements. Obstet Gynecol . 1998; 91: 1027–1034.
5.
Millicovsky G, Johnston MC. Maternal hyperoxia greatly reduces the incidence of phenytoin-induced cleft lip and palate in A/J mice. Science . 1981; 212: 671–672.
6.
Kaneko S, Otani K, Kondo T, et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology . 1992; 42 (suppl 5): 68–74.
7.
Ogawa Y, Kaneko S, Otani K, Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res . 1991; 8: 75–78.
8.
Buehler BA, Delimont D, van Waes M, Finnell RH. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med . 1990; 322: 1567–1572.
9.
Saari-Kemppainen A, Karjalainen O, Ylöstalo P, Heinonen OP. Fetal anomalies in a controlled one-stage ultrasound screening trial. A report from the Helsinki Ultrasound Trial. J Perinat Med . 1994; 22: 279–289.
10.
Gissler M, Rasimus A, Ritvanen A, Toukomaa H. Reproduction and its trends. Annual report of the National Research and Development Centre for Welfare and Health, Finland. Helsinki: National Research and Development Centre for Welfare and Health, 1996:2.
11.
Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy . 1997; 17: 561–564.
12.
Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia . 1999; 40: 1231–1236.
13.
Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists. Seizure disorders in pregnancy. Int J Gynecol Obstet . 1997; 56: 279–286.
14.
Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med . 2001; 344: 1132–1138.
15.
Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia . 1997; 38: 981–990.
16.
Kaneko S. Epilepsy, pregnancy, and the child. Epilepsia . 2000; 41 (suppl 9): 8–13.
17.
Janz D. Are antiepileptic drugs harmful when taken during pregnancy? J Perinat Med . 1994; 22: 367–377.
18.
Gram L. Vitamin supplementation. In: Thomson T, Gram L, Sillanpää M, Johannesen SI, eds. Epilepsy and pregnancy. Hampshire, UK: Wrightson Biomedical Publishing, 1997; 125–132.
19.
Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol . 1987; 21: 176–182.
20.
Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology . 1992; 42 (suppl 5): 32–42.
21.
Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod Biol . 1998; 78: 151–161.
22.
Crawford P, Appleton R, Betts T, Duncan J, Guthrie E, Morrow J. The women with epilepsy guidelines development group. Best practice guidelines for the management of women with epilepsy. Seizure . 1999; 8: 201–217.
23.
Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med . 2000; 343: 1608–1614.

Information & Authors

Information

Published In

Neurology®
Volume 60Number 4February 25, 2003
Pages: 575-579
PubMed: 12601095

Publication History

Received: July 1, 2002
Accepted: October 11, 2002
Published online: February 25, 2003
Published in print: February 25, 2003

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Erja Kaaja, MSc(pharm)
From the Department of Obstetrics and Gynecology (E. Kaaja and Drs. R. Kaaja and Hiilesmaa), Helsinki University Central Hospital; and Division of Pharmacology and Toxicology (E. Kaaja), Department of Pharmacy, University of Helsinki, Finland.
Risto Kaaja, MD PhD
From the Department of Obstetrics and Gynecology (E. Kaaja and Drs. R. Kaaja and Hiilesmaa), Helsinki University Central Hospital; and Division of Pharmacology and Toxicology (E. Kaaja), Department of Pharmacy, University of Helsinki, Finland.
Vilho Hiilesmaa, MD PhD
From the Department of Obstetrics and Gynecology (E. Kaaja and Drs. R. Kaaja and Hiilesmaa), Helsinki University Central Hospital; and Division of Pharmacology and Toxicology (E. Kaaja), Department of Pharmacy, University of Helsinki, Finland.

Notes

Address correspondence and reprint requests to Dr. Vilho Hiilesmaa, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, P.O. Box 140, 00029 HUCH, Finland; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Valproic Acid in Pregnancy Revisited: Neurobehavioral, Biochemical and Molecular Changes Affecting the Embryo and Fetus in Humans and in Animals: A Narrative Review, International Journal of Molecular Sciences, 25, 1, (390), (2023).https://doi.org/10.3390/ijms25010390
    Crossref
  2. Comparative analysis of three decades' experience in the management of pregnant women with epilepsy: a real-life scenario, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1254214
    Crossref
  3. Management of epilepsy during pregnancy and lactation, BMJ, (e074630), (2023).https://doi.org/10.1136/bmj-2022-074630
    Crossref
  4. A quality improvement initiative to improve folic acid supplementation counseling for adolescent females with epilepsy, Epilepsia, 64, 10, (2818-2826), (2023).https://doi.org/10.1111/epi.17723
    Crossref
  5. Elements of Teratology, First-Trimester Ultrasound, (77-91), (2023).https://doi.org/10.1007/978-3-031-24133-8_6
    Crossref
  6. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child, Cochrane Database of Systematic Reviews, 2023, 8, (2023).https://doi.org/10.1002/14651858.CD010224.pub3
    Crossref
  7. SAMe, Choline, and Valproic Acid as Possible Epigenetic Drugs: Their Effects in Pregnancy with a Special Emphasis on Animal Studies, Pharmaceuticals, 15, 2, (192), (2022).https://doi.org/10.3390/ph15020192
    Crossref
  8. Epilepsy and Pregnancy, CONTINUUM: Lifelong Learning in Neurology, 28, 1, (34-54), (2022).https://doi.org/10.1212/CON.0000000000001056
    Crossref
  9. Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide, Therapeutic Advances in Neurological Disorders, 15, (175628642211016), (2022).https://doi.org/10.1177/17562864221101687
    Crossref
  10. Adverse fetal and neonatal outcomes following in‐utero exposure to oxcarbazepine: A systematic review and meta‐analysis, British Journal of Clinical Pharmacology, 88, 8, (3600-3609), (2022).https://doi.org/10.1111/bcp.15413
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share